Myositis Awareness Month

Press release: MAM Resolution in US House of Representatives

COLUMBIA, MD, UNITED STATES, May 1, 2025 /EINPresswire.com/ — May is Myositis Awareness Month, a time dedicated to raising awareness about a rare autoimmune disease that affects muscles and skin. The Myositis Association (TMA) leads this initiative, aiming to educate the public, support those living with myositis, and advocate for better treatments and a cure….

Continue Reading

TMA member and medical advisors pivotal in patient reported outcomes research

TMA is excited to announce that The Journal of Rheumatology recently published a pivotal study titled “The Dermatomyositis Disease Symptom Questionnaire (DM-DSQ): A Measure to Assess the Patient Experience of Dermatomyositis Symptoms.” This groundbreaking research, led by an international team of myositis experts, including TMA medical advisors Dr. Lisa Christopher-Stine, Dr. Namita Goyal, and Dr….

Continue Reading

TMA Hosts Patient Stories on Rare Disease Day

Rare Disease Day Summit highlights myositis and the 7000 other rare diseases affecting one in ten Americans COLUMBIA, MD, UNITED STATES, February 27, 2025 /EINPresswire.com/ — The Myositis Association (TMA), in collaboration with the Myositis International Health and Research Collaborative Alliance (MIHRA) and Nori’s Fight, will host, We Care for Rare Summit: Celebrating Myositis Science…

Continue Reading

TMA board vice chair testifies in support of Georgia’s Hope for Patients Act

On Monday, February 10, 2025, Rich DeAugustinis, Vice Chair of TMA’s Board of Directors, testified to the Georgia Senate Committee on Health and Human Services in support of the Georgia Hope for Patients Act (S.B. 72). This proposed legislation, sponsored by Georgia Senator Matt Brass, will allow patients who have severely debilitating or life-threatening illnesses to…

Continue Reading

Rare diseases need more research, not less

By Paula Eichenbrenner, TMA Executive Director and Laurie Boyer, TMA Board of Directors Chair At TMA, we believe research is the key to better treatments and a brighter future for those living with myositis. Our mission includes an important commitment to “fund innovative myositis research.” In fact, TMA has invested nearly $10 million into research…

Continue Reading